Poster Spotlights CD2 Pathway as a Differentiated T Cell Costimulation Approach for the Treatment of Solid and Hematological Malignancies Modular…
New Biomarkers of Response and Resistance that Suggest Pepinemab Could Offer New Combination Treatment OptionsROCHESTER, N.Y., Nov. 10, 2022 (GLOBE…
Recruiting has Commenced for Phase 1/2a Clinical Trial of IMM-1-104 in Advanced Solid Tumors with RAS Mutations (NCT05585320), with the…
Updated data support the proof of concept of using an iNKT agonist monotherapy (PORT-2) to induce immune response for patients…
Presentations highlight use of Nurix’s first-in-class CBL-B inhibitor NX-0255 to enhance growth and profile of T cells for cell therapy…
Paper published in the November 2022 issue of Podiatry Management(Robert J. Snyder, DPM, Cyaandi Dove, DPM, and Vickie Driver, DPM,…
NEW YORK, Nov. 03, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer…
Prevalence of esophageal and gastric varices in patients with compensated NASH cirrhosis and portal hypertensionBiochemical and imaging profiles in 271…
NEW YORK, Oct. 31, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer…
PRESS RELEASE: REGULATED INFORMATION 28 October 2022, 07:01 CEST Biocartis Announces Conversion of a Portion of the Convertible Term Loan…